Atlanta MedTech Startup Raises $10 Million Series A

A small but mighty team in Atlanta is tackling one of medicine’s biggest challenges: cutting postoperative pain while reducing opioid use.


Shyamy Sastry and his team at the medical device startup Synaptrix, Inc. have developed a proprietary system NOVABLOC™, which is looking to bring new options to the modern pain management world. Its human feasibility studies have demonstrated more than 20 days of pain relief with a single treatment.


The startup says it is “committed to reducing opioids” while bringing more user-friendly options to the pain management space.


“Modern day treatments for postoperative pain management are largely insufficient. They are either plagued by short-lasting pain control, limit physical rehabilitation, or invite opioid use,” said CEO Sastry. “The NOVABLOC™ system is a groundbreaking neuromodulation technology designed to deliver 20+ days of pain relief without impacting motor function or touch. Altogether, the system treats postoperative pain for days to weeks while promoting rehabilitation and reducing the need for opioids.”



As Sastry explained to Hypepotamus, neuromodulation is a “treatment that uses electrical or chemical stimulation to modify neural activity.” For NOVABLOC, that means delivering “electrical stimulation to selectively reduce neural activity transmitted by pain fibers.”


Keep Reading Here: https://hypepotamus.com/startup-news/synaptrix-raises-10-million/

Georgia’s Life Sciences Momentum is Getting Noticed Nationally.

August 21, 2026
Genetic Engineering & Biotechnology News (GEN) has named Georgia #4 among its “Next 5 States” for emerging U.S. biopharma clusters . The article highlights UCB’s planned $2 billion investment at in Gwinnett County, Micron Biomedical’s new Alpharetta facility, Manus Bio’s expansion in Augusta, Science Square, Emory University, the CDC — and Georgia Life Sciences’ 10-year Life Sciences Roadmap . This recognition is exciting. But even more importantly, it validates the work happening across our entire ecosystem — and perfect momentum as we head into the 2026 Georgia Life Sciences Summit next week. Read more by visiting: Next 10 U.S. Biopharma Clusters

BIO Supports PDUFA VIII Commitment Letter and Urges Timely Reauthorization

August 17, 2026
Biotechnology Innovation Organization (BIO) Senior Vice President of Science & Regulatory Affairs Annetta Beauregard issued the following statement on the release of the Prescription Drug User Fee Act (PDUFA) VIII commitment letter: “For more than 30 years, PDUFA has helped deliver hundreds of new medicines to American patients. As a lead industry negotiator for the PDUFA VIII agreement, BIO supports the PDUFA VIII commitment letter and its strengthening of regulatory review, advancing innovation, and helping deliver safe and effective treatments to patients. “Specifically, the PDUFA VIII agreement includes important commitments that bolster the FDA’s core review activities, ensure accountability for predictable performance, improve financial sustainability and improve communication, transparency and efficiency. “Timely, bipartisan reauthorization of PDUFA is vital for protecting the health of Americans, strengthening U.S. competitiveness, and maintaining America’s global leadership in medical innovation. BIO is committed to working with Congress to ensure reauthorization by September 30, 2027.” The FDA has announced plans to hold a hybrid public meeting at 9am on 9/16 to discuss the proposed enhancements for the reauthorization of PDUFA for fiscal years (FYs) 2028 through 2033. Learn More about PDUFA and the PDUFA VIII commitment letter HERE .

Georgia Life Sciences Submits Comments on Medicare Drug Price Negotiation Program

August 17, 2026
Representing Georgia’s life sciences community, GLS emphasized the importance of advancing policies that improve affordability and patient access while preserving the environment necessary for continued biomedical innovation. In its comments, GLS urged CMS to maintain a framework grounded in FDA regulatory determinations and raised concerns about how certain proposed policies could affect post-approval research and development, investment in new indications, and patient access to innovative therapies. GLS also encouraged CMS to consider the broader implications for healthcare delivery, including the potential impact on patients and providers in rural and underserved communities. As federal drug pricing policy continues to evolve, Georgia Life Sciences will continue to advocate for approaches that balance affordability, access, and innovation while ensuring Georgia’s life sciences community has a voice in the policymaking process. Read Georgia Life Sciences’ full comments to CMS ( click here ).
MORE POSTS